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ABSTRACT
Very limited data are available in the literature to elucidate the aetiology of invasive mould infec-
tions in Latin America. Here we report that Aspergillus species caused only half of such cases in a 
cohort study conducted over 21 months in a university hospital in Porto Alegre, Southern Brazil. 
Fusarium spp. were the second most prevalent moulds (20.7%), followed by Zygomycetes (13.8%). 
The importance of obtaining local epidemiological data for adequately guiding empirical antifungal 
therapy is reinforced.
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INTRODUCTION
Several authors have reported an increasing 
incidence of invasive fungal diseases (IFDs), 
especially in patients with haematologi-
cal malignancies and in those undergoing 
haematological stem cell transplantation 
(HSCT).1-6 Since these are difficult to di-
agnose conditions, with an associated high 
mortality rate, empirical antifungal therapy 
is widely used for patients with a suspected 
IFD. However, the effectiveness of any em-
pirical treatment depends on knowledge of 
causative agents. Candida species are by far 
the most common fungi causing IFDs in hu-
mans.7 However, many centres over the past 
decade have reported a marked reduction in 
the incidence of Candida bloodstream infec-
tions as a result of fluconazole prophylaxis.8 
In contrast, there has been an increment in 
the incidence of invasive mould infections,9,10 
particularly due to species of Aspergillus, 
Fusarium, and Zygomycetes.2,3,9,10
The purpose of this study was to describe the 
fungal agents isolated from patients admmitted 
to a haematological unit in Brazil. All cases in-
cluded in this cohort occurred before the instal-
lation of High-Effi ciency Particulate Air (HEPA) 
fi ltration in the haematological unit. 
MATERIAL AND METHODS
This was a retrospective cohort study con-
ducted to assess the distribution of filamen-
tous fungi causing IFD in patients with hae-
matological malignancies and those who had 
undergone HSCT. The study was performed 
at the Hospital de Clínicas de Porto Alegre 
(HCPA), a 750-bed tertiary-care university 
hospital located in Porto Alegre, Southern 
Brazil. The files from the Mycology Labo-
ratory were hand searched from February 
2004 to December 2006, in an attempt to 
select for cases of IFD caused by moulds. 
Medical records from these patients were 
reviewed. Patients with endemic mycoses 
or yeast infections were not included in the 
study, as well as those in whom the agent 
was not identified in culture. All IFDs were 
classified according to the revised EORTC/
MSG consensus criteria,11 and only cases of 
proven/probable infections were studied. 
Standard mycological procedures were 
performed for the analysis of clinical sam-
ples, including microscopy and culture. De-
scriptive statistics were used to summarise 
the data. Statistical analysis was performed 
with SPSS 16.0. Normally distributed quan-
titative data were analysed with Student’s 
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t-test, while the non-parametric Mann-Whitney test was 
used for variables with asymmetric distribution. Categor-
ical data were evaluated with chi-square or Fisher’s exact 
test. Survival analyses were performed 6 weeks after IFD 
was diagnosed using Kaplan-Meyer analysis and the log 
rank test. P-values of < 0.05 were considered statistically 
significant. This article is part of a more comprehensive 
project submitted to and approved by the Ethics Com-
mittee of Hospital de Clínicas de Porto Alegre (GPPG 
07068).
During the study period, HSCT patients received an-
tifungal prophylaxis with fluconazole at 200 mg daily. 
Patients on high doses of chemotherapy for acute my-
eloid leukaemia, acute lymphoblastic leukaemia, or high 
risk myelodisplasic syndrome received itraconazole cap-
sules (200 mg once a day with an acid drink).
RESULTS
A total of 29 patients with IFD caused by moulds were iden-
tifi ed. Patients were mostly female (n = 15) and mean age 
was 31.7 year-old. Sixteen patients (55.2%) had been sub-
mitted to HSCT, including allogeneic (n = 12; 41.4%) and 
autologous (n = 4; 13.8%) recipients. Only 24.1% (n = 7) of 
patients were not neutropenic at the time of IFD diagnosis.
As shown in Table 1, only 58.6% of cases were caused by 
Aspergillus species (n = 17). Fusarium spp. were the second 
most prevalent fi lamentous fungi (n = 6; 20.7%), followed 
by Zygomycetes (n = 4; 13.8%). Other fungi included spe-
cies of Curvularia and Trichoderma (one case each; 3.4%). 
Most fungal infections were classifi ed as proven IFD (n = 20, 
69.0%) and 9 cases were probable (31.0%). Most IFDs oc-
curred in the context of febrile neutropenia (n = 22; 75.9%). 
Clinical samples were paranasal sinus biopsy (n = 15; 51.7%), 
respiratory tract specimen (bronchoalveolar lavage/spu-
tum) (n = 9; 31%), blood culture (n = 2; 6.9%), skin biopsy 
(n = 2; 6.9%), and lung biopsy (n = 1; 3.4%). Aspergillus species 
were recovered in 60% of cases of invasive fungal sinusitis (9/15), 
followed in frequency by Zygomycetes (n = 3; 20%), Fusarium 
species (n = 2; 13.3%), and Curvularia spp. (n = 1; 6.7%). Sur-
gical debridement of paranasal sinuses was performed for most 
patients with invasive fungal rhinosinusitis (93.3%).
Overall mortality 6 weeks after the diagnosis of IFD was 
41.9%. Similar mortality rates were observed for patients 
with invasive aspergillosis (35.3%), fusariosis (50.0%), and 
zygomycosis (50.0%) (p = 0.283). Mortality was 50.6% for 
patients with proven IFD and 21.4% for those with probable 
IFD (p = 0.127).
DISCUSSION
The medical importance of IFDs has markedly increased in the 
last decades. The causes for that are multifactorial. In special, 
there has been an increment in the proportion of individuals 
at risk as a result of immunosuppression, particularly amongst 
haematological patients. In addition, aggressive medical inter-
ventions have allowed critically ill patients to survive longer, in-
creasing their overall risk to acquire fungal infections.5,12
In the present study, we showed the distribution of 
fi lamentous fungi causing invasive fungal diseases at the 
haematology unit of HCPA, a reference medical centre in 
Southern Brazil. Roughly, half of infections were caused by 
Aspergillus species, especially A. fumigatus and A. fl avus (the 
latter usually in association with invasive fungal rhinosi-
nusitis). A large proportion (41.4%) of IFDs was associated 
with fungi other than Aspergilli. Fusarium species caused 
20.7% of invasive mould infections, followed in frequency 
by Zygomycetes (13.8%). Fusarium species are known to 
cause a broad spectrum of infections in humans, including 
superfi cial, locally invasive and disseminated infections, par-
ticularly in immunocompromised patients with prolonged 
neutropenia.13 In addition, Fusarium spp. are highly resist-
ant to antifungal drugs.14 Zygomycosis, which seems to be 
an emerging problem for many medical centres,4,6 is also a 
very diffi cult to treat infection, usually requiring a combina-
tion of surgical debridement and high dose treatment with 
amphotericin B. Because voriconazole is inactive against the 
Zygomycetes, the emergence of these fungi might compli-
cate voriconazole use in the empirical setting. 
The emergence of mould infections have been docu-
mented in several studies. Similarly to our fi ndings, Neofy-
tos et al.5 documented that most (59.2%) IFDs in HSCT 
recipients were caused by Aspergillus species, followed in fre-
quency by Candida spp. (24.8%), Zygomycetes (7.2%), and 
other moulds (6.8%). In the study by Horn et al.20 Aspergil-
lus spp. caused 14.8% of all IFDs in a cohort of 1710 patients 
enrolled in 22 sites in the United States (PATH Alliance 
study). A small number of IFDs caused by other fungi was 
also observed, including species of Paecilomyces, Scedospo-
rium, Alternaria, Acremonium, Fusarium, and Zygomycetes. 
Garcia-Vidal et al.21 observed that Aspergillus species caused 
88% of invasive mould infections following allogenic HSCT. 
Several authors have stressed that IFDs caused by different 
moulds may require specifi c strategies in terms of diagnosis, 
treatment, and prophylaxis. Obtaining local epidemiological 
data is therefore a crucial step in organising health care units 
and planning therapeutic interventions.
Although numerous studies in the last 10 years have doc-
umented the epidemiology of Candidaemia in Brazil,15-17 lit-
tle information is available on invasive aspergillosis (IA) or 
other invasive mould diseases. A previous study performed 
in Porto Alegre demonstrated that 82% of cases of IA were 
not diagnosed before autopsy.18 This reality seems similar 
in several other countries: it is estimated that 20-80% of IA 
cases are not diagnosed before death, frequently because of 
lack of clinical suspicion.9,19 Since the frequency of autopsy 
is at a decrease in the western world, physicians risk ending 
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up with an incorrect perception that invasive mould infec-
tions rarely occur in the clinical practice.
To the best of our knowledge, only two cohort studies 
have so far documented the epidemiology of IFD in Bra-
zil. The distribution of Aspergillus species causing IFD at 
Hospital de Clínicas da Universidade Federal do Paraná 
– another referral centre for allogeneic HSCT in South-
ern Brazil – was recently published.12 A total of 24 cases of 
proven/probable IA were detected over a 10-year period in 
that investigation, including 11 proven IA cases. The re-
ported incidence of 3% was probably underestimated, since 
galactomannan testing was not available at the time of the 
study. Overall mortality was 70% after 30 days of follow-up. 
Non-Aspergillus moulds were recovered from 163 additional 
Table 1. Patient demographic data and main agents of invasive fungal disease caused by moulds
  Patient Sex Age Underlying HSCT Neutropenia Sites Agent EORTC/ MSG Survival
   disease  at  of infection  criteria status 
     diagnosis    (at 6 weeks)
1 M 32 ALL Allogeneic Yes Paranasal sinuses A. fumigatus Proven Died
2 F 17 HD Autologous No Lungs A. fumigatus Probable Survived
3 M 33 ALL Allogeneic Yes Paranasal sinuses A. fumigatus Proven Died
4 F 52 MM - Yes Paranasal sinuses A. flavus Proven Died
5 F 15 AML Allogeneic No Lungs A. fumigatus Probable Survived
6 F 37 AML Allogeneic No Paranasal sinuses A. fumigatus Probable Survived
7 M 18 ALL Allogeneic Yes Skin Fusarium sp. Proven Died
8 M 21 ALL Allogeneic Yes Paranasal sinuses Fusarium sp. Proven Died
9 F 81 MM - Yes Bloodstream Fusarium sp. Proven Survived
10 M 40 AML - Yes Lungs A. fumigatus Proven Died
11 M 24 HD Autologous No Paranasal sinuses Absidia sp. Proven Died
12 M 25 AML - Yes Paranasal sinuses Aspergillus sp. Proven Died
13 M 45 AML Allogeneic Yes Paranasal sinuses Aspergillus sp. Proven Died
14 F 11 ALL - Yes Paranasal sinuses A. flavus Proven Survived
15 M 39 AML - Yes Paranasal sinuses A. fumigatus Proven Died
16 M 35 ALL - Yes Lungs A. fumigatus Probable Died
17 F 15 ALL - Yes Skin Fusarium sp. Proven Died
18 F 38 Aplasia - No Paranasal sinuses Fusarium sp. Proven Died
19 F 44 CML Allogeneic Yes Paranasal sinuses Rhizopus sp. Proven Died
20 M 5 Aplasia - Yes Paranasal sinuses Mucor sp. Proven Survived
21 M 63 ALL - Yes Lungs A. fumigatus Probable Survived
22 F 31 AML - Yes Paranasal sinuses A. niger Proven Died
23 M 46 CLL Allogeneic Yes Lungs Trichoderma sp. Probable Died
24 F 57 NHL Autologous Yes Bloodstream Fusarium sp. Proven Died
25 F 26 Aplasia Allogeneic No Lungs Rhizopus sp. Probable Died
26 M 40 AML Autologous No Lungs A. fumigatus Probable Survived
27 F 29 ALL - Yes Paranasal sinuses Curvularia sp. Proven Died
28 F 40 AML Allogeneic Yes Lungs A. fumigatus Proven Died
29 F 15 AML Allogeneic Yes Lungs A. fumigatus Probable Survived
ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; BAL, bronchoalveolar lavage; CLL, chronic lymphocytic leu-
kaemia; CML, chronic myeloid leukaemia; EORTC/MSG: European Organization for Treatment of Cancer/Mycoses Study Group; F, 
female; HD, Hodgkin disease; HSCT, haematological stem cell transplantation; M, male; MM, multiple myeloma; NHL, non-Hodgkin 
lymphoma.
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patients but no details were provided. Partial results from a 
multicenter survey study performed in Brazil were recently 
presented in abstract form.22 Considering patients with 
proven/probable infections only, the incidence of IFD in 
HSCT recipients and patients with acute myeloid leukae-
mia and myelodysplastic syndrome was 6.7% in that inves-
tigation. Twenty-fi ve patients (out of 460) had proven IFD. 
Also, this may also be underestimated, since serum galac-
tomannan testing was not routinely performed. Similarly 
to our fi ndings, fusariosis was the second leading cause of 
invasive mould disease, being more common than zygo-
mycosis. 
One remarkable fi nding of our study was the elevated 
proportion of proven IFD cases (69.0%), in comparison to 
probable cases. This was achieved due to an aggressive policy 
of computed tomography imaging of the paranasal sinususes 
in patients with febrile neutropenia, which frequently trig-
gers the performance of paranasal sinuses biopsies. Accord-
ingly, approximately 50% of patients in the current series 
had invasive fungal rhinosinusitis. The diagnosis of these 
conditions is actually dependent on demonstration of tissue 
invasion by fungi, and the paranasal sinuses are more easily 
reached for invasive medical procedures than the lungs.
CONCLUSION
In conclusion, here we demonstrated that 41.4% of invasive 
mould infections were associated with fungi other than those 
belonging to the Aspergillus genus. Fusarium spp. was the sec-
ond most frequently recovered fungi. Of concern is the fact 
that Zygomycetes were the second aetiology of invasive rhi-
nosinusitis in this study. Epidemiological surveillance is nec-
essary in order to monitor the dynamics of these infections.
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